Viridian Therapeutics, Inc.
- VRDN
- NASDAQ
- Biotechnology
- Thyroid Eye Disease Treatment
- Monoclonal Antibody
$19.03
Today −2.71%Quote Oct 16, 2026, 08:00 PM UTC
−13.22%over the last month
Max drawdown −17.6%From 1-month high −14.0%3 months +2.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$2.16B
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$36.43
+91.4% from here
Floor
$18.67
1.9% below price
Where the price sits
16 analysts
Analyst range, low to high
$26.00$43.00
- Price $19.03
- Resistance $19.05–$19.24
- Consensus $36.43
The price is just above its floor and right under resistance. Analysts' average target sits about 91% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about VRDNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $284,000
- License$233,00082.0%
- Collaboration$51,00018.0%
Industry
Biotechnology
Employees
252